Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study - Takeaway - MDSpire

Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study

Share

  • 1

    The study enrolled 120 AHF patients with LVEF ≤40% to evaluate combined ARNI and SGLT2 inhibitor therapy post-hemodynamic stabilization.

  • 2

    Significant increases in urine volume and diuretic response were observed on day 1, stabilizing above baseline levels during the study.

  • 3

    Cardiovascular biomarkers improved, with decreased NT-proBNP levels and increased LVEF, while eGFR remained unaffected.

  • 4

    The findings suggest potential benefits of combined ARNI and SGLT2 inhibitor therapy in AHF management, warranting further randomized trials.

  • 5

    Limitations include the short-term nature of the study and absence of a control group, hindering definitive causal attribution of effects.

Original Source(s)

Related Content